Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-12-19
2006-12-19
Owens, Amelia A. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S271000, C548S431000
Reexamination Certificate
active
07151116
ABSTRACT:
The invention provides novel apoptosis-inducing compounds that include isolated, purified isoapoptolidin, and selectively functionalized isoapoptolidin derivatives and stereoisomers thereof; selectively functionalized apoptolidin derivatives and stereoisomers thereof; and deglycosylated isoapoptolidin and selectively functionalized derivatives and stereoisomers thereof. The isoapoptolidin, apoptolidin, and deglycosylated isoapoptolidin derivatives may be functionalized by substituting any or all of the methoxyl or hydroxyl groups of the parent molecule. Pharmaceutical compositions and methods for using the compounds are also provided.
REFERENCES:
patent: 5962290 (1999-10-01), Khosla et al.
patent: 6548485 (2003-04-01), Khosla et al.
patent: 2002/0049168 (2002-04-01), Khosla et al.
patent: 2002/0077300 (2002-06-01), Khosla et al.
Salmon et al, Understanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of F0F1-ATPase, PNAS, 97(26), pp. 14766-14771, Dec. 19, 2000.
Hayakawa, et al., “Structure of apoptolidin, a specific apoptosis inducer in transformed cells,” J. Am. Chem. Soc. (1998) 120:3524-3525.
Pennington, et al., “Toward a stable apoptolidin derivative: identification of isoapoptolidin and selective deglycosylation of apoptolidin,” Org. Lett. (2002) 4:3823-3825.
Salomon, et al., “Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase,” Chem. Biol. (2000) 54:1-10.
Salomon, et al., “Structure-activity relationships within a family of selectively cytotoxic macrolide natural products,” Org. Lett. (2001) 3:57-59.
Salomon, et al., “Understanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of F0F1-ATPase,” Proc. Natl. Acad. Sci.USA (2000) 97:14766-14771.
Wender, et al., “Isoapoptolidin: structure and activity of the ring-expanded isomer of apoptolidin,” Org. Lett. (2002) 4:3819-3822.
Wender, et al., “Toward a structure-activity relationship for apoptolidin: selective functionalization of the hydroxyl group array,” Org. Lett. (2003) 5:487-490.
Wender, et al., “Facile synthesis access to and biological evaluation of the macrocyclic core of apoptolidin,” Org. Lett. (2003) 5:2299-2302.
Jankowski Orion D.
Tabet Elie A.
Wender Paul A.
Board of Trustees of The Leland Stanford Junior University
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Owens Amelia A.
LandOfFree
Apoptolidin analogs and derivatives for inducing apoptosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Apoptolidin analogs and derivatives for inducing apoptosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Apoptolidin analogs and derivatives for inducing apoptosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3698354